In partnership with
Q3 M&A Deal Values Surge by 29% While Equity Issuance Slips; GeneDx Revenue Soars 77% š
More Strategic Moves You Have to Know, Donāt Miss Out!
Remember to move the mail to the Primary inbox if this mail is in other inboxes.
We are excited to announce the launch of our new AI Event Alert user interface. With over 70% accuracy in predicting "Very Bullish" and "Very Bearish" stocks, letās make your investment simple with StockNews.ai today! |
Hereās what you need to know today, 10/29.
*The information below reflects stock prices as of 11:30am EDT. Please note that stock prices may have changed since that time.
PRNewsWire
BullishShortTerm 0.45%SPGIEarnings
S&P Global Market Intelligence Quarterly Report Finds Global M&A Continues to Rebound while IPO Activity Continues to Falter in Q3
- Global M&A announcements rose 0.36% quarter-over-quarter in Q3 2024.
- Equity issuance dropped nearly 33%, totaling $65.63 billion.
- M&A deal values increased 29.1% year-over-year to $708.74 billion.
- IPO activities may slow due to market volatility and upcoming holidays.
- 2025 may see optimism from rate reductions by the Federal Reserve.
Business Wire
BullishLongTerm 0.43%NESRM&A
NESR Acquires Stake In SALTTECH BV To Scale Up Circular Water Technology
- NESR acquired a minority stake in Salttech for thermal desalination technology.
- The DyvarĀ® technology enhances NESR's water solutions in the MENA region.
- NESR can become the majority owner of Salttech in the future.
- This partnership aims to tackle water challenges in the energy sector.
- Collaboration with Salttech affirms NESR's commitment to sustainable innovation.
Business Wire
Very BullishLongTerm 35.44%WGSEarnings
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
- GeneDx reported 77% revenue growth in exome and genome tests for Q3 2024.
- Company achieved profitability, delivering positive adjusted net income ahead of expectations.
- Expanded genomic testing coverage through Medicaid, increasing accessibility for pediatric patients.
- Achieved over 700,000 sequenced clinical exomes and genomes, enhancing growth outlook.
- Launched rapid whole genome sequencing, revolutionizing newborn screening standards.
GlobeNewsWire
BullishShortTerm 2.83%HAOEarnings
Haoxi Health Technology Limited Reports Financial Results for Fiscal Year Ended June 30, 2024
- HAO's fiscal 2024 revenue grew by 72% to $48.52 million.
- Net income increased 33% to $1.29 million, reflecting operational growth.
- Average revenue per client rose from $71,830 to $89,355 in 2024.
- Strategic partnerships and a follow-on offering raised $12 million.
- Cash and equivalents surged to $6.66 million from $1.20 million.
GlobeNewsWire
BearishShortTerm 3.34%HTLDEarnings
Heartland Express, Inc. Reports Operating Results for the Third Quarter of 2024
- Heartland Express reported Q3 2024 revenue of $259.9 million, net loss of $9.3 million.
- Operating ratio of 102.7% indicates inefficiencies in current operations due to low demand.
- Encouraging signs of freight demand recovery noted, but significant improvement expected by 2025.
- Acquisition debt repayments reduced significantly; substantial efforts in operational integration ongoing.
- The company declared a quarterly dividend of $0.02 per share despite ongoing challenges.
Your IRA, made to order
Choose where and when you want to retire, and a Betterment IRA can help make your money hustle all the way there.
Want something new? Choose one for the next newsletter topicāØ Poll closes on every Friday at 11:59pm! |
|
Login or Subscribe to participate in polls. |
Like StockNews.AI? Unlock more functions by joining our Premium or Pro Plan š š
Disclaimer: The content provided in this Email should be used for informational purposes only and in no way should be relied upon for financial advice.
Reply